Author: Pacific Research Institute

Home > Articles posted by Pacific Research Institute (Page 6)

May 28, 2020 Coronavirus, Issues

By Henry I. Miller, M.S., M.D. and Andrew I. Fillat ‘Metadata” might sound like something that “Star Trek‘s” Spock would oversee, but it is real and increasingly familiar, as the result of stories about wiretaps and security. The easiest-to-understand example of it is information about the time, duration, originating number, and destination number of a phone call – but without any of the content (i.e. words spoken) of the call. Metadata might also indicate from its format that a field on a...

May 27, 2020 Blog, Coronavirus, Policy Proposals

By Henry I. Miller, M.S., M.D. and Andrew I. Fillat Every day seems to bring some new, unexpected, unpleasant revelation about the SARS-CoV-2 and the illness it causes, COVID-19. The infection has a long, often asymptomatic incubation period, high transmissibility, the ability to infect many human tissues, and, frequently, rapid deterioration of the clinical course. Some curious aspects of the infection, such as long duration of symptoms, multi-organ involvement, blood clots, and patients’ ability to tolerate extremely low blood oxygen levels have...

May 20, 2020 Coronavirus, Innovation

A COVID-19 Vaccine by January? Here’s Why It’s Possible But Not Likely By Christopher Curley The timeline to develop a safe, effective vaccine to fight a virus is typically counted in years — or even decades. But with the COVID-19 pandemic affecting millions around the world and killing hundreds of thousands of people, the race is on to produce a vaccine faster than ever before. President Donald Trump has said a vaccine could be available by January, which would be an unprecedented development cycle. But how realistic is that? Experts...

April 28, 2020 Coronavirus, Policy Proposals, Radio

PRI President, CEO, and Thomas W. Smith Fellow in Health Care Studies Sally C. Pipes joins PRI's Next Round podcast to discuss some of the health care challenges that have popped up during the coronavirus crisis, including a renewed push for single-payer and calls for prescription drug price controls and a “Buy America” mandate for drug manufacturing. We also discuss a few positives changes that have occurred despite these tough times – the rise of telehealth and the rolling back...

April 10, 2020 Coronavirus

As Americans endure the privations necessary to “flatten the curve” of new cases of coronavirus COVID-19, we wish that our leaders could manage even a fraction of the comity and tolerance exhibited every day by ordinary people throughout this country. Sadly, we see too much of the opposite. Putting aside the machinations of politicians, there seems to be a widespread need to blame any misstep, or even uncertainty, on somebody or something. The ubiquitousness of social media and the internet drives the...

April 6, 2020 Blog, Coronavirus, Multimedia, Radio

PRI Senior Fellow in Health Care Studies Dr. Henry Miller joins PRI's Next Round podcast with an update on the fight against the coronavirus. He offers much-needed perspective on what public health officials are doing to “flatten the curve,” efforts to find vaccines and treatments, the efforts of other countries to contain the virus, when we can expect to get back to business as usual, and whether we should expect more viruses like these going forward. https://youtu.be/1FlElnaB3Ps...

April 6, 2020 Blog, Coronavirus

The federal government’s efforts to combat the ongoing coronavirus pandemic illustrate why we shouldn’t put our full trust in government to find a cure. After all, they badly botched the testing, costing valuable time in identifying new cases and limiting its spread. Fortunately, private-sector innovators are leading where government has underwhelmed, conducting speedy research and development into potentially life-saving cures, while providing critical support in other areas where government action was lacking. The first version of test kits from the Centers for...

April 2, 2020 Blog, Coronavirus

Title: COVID-19 Pandemic Delaying Treatments of Hematologic Cancers By: John Schieszer Institutional restrictions due to the coronavirus disease 2019 (COVID-19) pandemic are taking a large toll on patients with hematologic cancers. Some medical centers have canceled treatments and all centers have altered their policies and procedures. Starting in March, elective and semielective surgical procedures at most hospitals throughout the United States were put on hold, and uncertainty remains regarding when these procedures will start up again. . . . . . Because there is...

March 24, 2020 Price and Costs

SAN FRANCISCO – As prescription drug pricing and accessibility has become a greater topic of discussion during the current coronavirus pandemic, a new series of animated videos launched today by the Center for Medical Economics and Innovation at the Pacific Research Institute aims to guide Americans through the “drug pricing maze”. The new series will educate viewers on how the current drug pricing system is fueled by misguided policies that drive up costs, and how free-market reforms would steer us toward...

March 2, 2020 Blog, Coronavirus, Industry Trends

Title: As U.S. Sees COVID-19 Infections Spike, Some Worry About 'Grave Errors' By Adam Smith In the beginning, the few reports of a newly discovered virus seemed inconsequential and distant. The coronavirus was causing pneumonia in scores of people, but those patients were in a faraway province of China, Hubei, that most outside that nation had never heard of. “There is no evidence that the new virus is readily spread by humans, which would make it particularly dangerous, and it has not been...

March 2, 2020 Blog, Coronavirus, Policy Proposals

The Green New Dealers want us to think we have to either live more austere lives under coercive government policies or destroy the planet. Opponents of their plan, the theory goes, are willing to sacrifice the environment for short-term financial prosperity for the elite few. Nothing could be further from the truth. Meeting Americans’ needs, especially those of the neediest, requires free markets that can realize and reward the benefits of technological innovations, big and small. Big innovations are those such as the...